Sezary syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 9: Line 9:
*Sezary syndrome must be differentiated from other [[Disease|diseases]] that cause:<ref name="pmid23197199">{{cite journal |vauthors=Yamashita T, Abbade LP, Marques ME, Marques SA |title=Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update |journal=An Bras Dermatol |volume=87 |issue=6 |pages=817–28; quiz 829–30 |date=2012 |pmid=23197199 |pmc=3699909 |doi= |url=}}</ref><ref name="pmid249363243">{{cite journal |vauthors=Olek-Hrab K, Silny W |title=Diagnostics in mycosis fungoides and Sezary syndrome |journal=Rep Pract Oncol Radiother |volume=19 |issue=2 |pages=72–6 |date=March 2014 |pmid=24936324 |pmc=4054990 |doi=10.1016/j.rpor.2013.11.001 |url=}}</ref><ref name="pmid18652582">{{cite journal |vauthors=Klemke CD, Brade J, Weckesser S, Sachse MM, Booken N, Neumaier M, Goerdt S, Nebe TC |title=The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers |journal=Br. J. Dermatol. |volume=159 |issue=4 |pages=871–80 |date=September 2008 |pmid=18652582 |doi=10.1111/j.1365-2133.2008.08739.x |url=}}</ref><ref name="pmid21985996">{{cite journal |vauthors=Scala E, Abeni D, Palazzo P, Liso M, Pomponi D, Lombardo G, Picchio MC, Narducci MG, Russo G, Mari A |title=Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome |journal=Int. Arch. Allergy Immunol. |volume=157 |issue=2 |pages=159–67 |date=2012 |pmid=21985996 |doi=10.1159/000327553 |url=}}</ref><ref name="pmid3528307">{{cite journal |vauthors=Chu AC, Robinson D, Hawk JL, Meacham R, Spittle MF, Smith NP |title=Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis |journal=J. Invest. Dermatol. |volume=86 |issue=2 |pages=134–7 |date=February 1986 |pmid=3528307 |doi= |url=}}</ref>
*Sezary syndrome must be differentiated from other [[Disease|diseases]] that cause:<ref name="pmid23197199">{{cite journal |vauthors=Yamashita T, Abbade LP, Marques ME, Marques SA |title=Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update |journal=An Bras Dermatol |volume=87 |issue=6 |pages=817–28; quiz 829–30 |date=2012 |pmid=23197199 |pmc=3699909 |doi= |url=}}</ref><ref name="pmid249363243">{{cite journal |vauthors=Olek-Hrab K, Silny W |title=Diagnostics in mycosis fungoides and Sezary syndrome |journal=Rep Pract Oncol Radiother |volume=19 |issue=2 |pages=72–6 |date=March 2014 |pmid=24936324 |pmc=4054990 |doi=10.1016/j.rpor.2013.11.001 |url=}}</ref><ref name="pmid18652582">{{cite journal |vauthors=Klemke CD, Brade J, Weckesser S, Sachse MM, Booken N, Neumaier M, Goerdt S, Nebe TC |title=The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers |journal=Br. J. Dermatol. |volume=159 |issue=4 |pages=871–80 |date=September 2008 |pmid=18652582 |doi=10.1111/j.1365-2133.2008.08739.x |url=}}</ref><ref name="pmid21985996">{{cite journal |vauthors=Scala E, Abeni D, Palazzo P, Liso M, Pomponi D, Lombardo G, Picchio MC, Narducci MG, Russo G, Mari A |title=Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome |journal=Int. Arch. Allergy Immunol. |volume=157 |issue=2 |pages=159–67 |date=2012 |pmid=21985996 |doi=10.1159/000327553 |url=}}</ref><ref name="pmid3528307">{{cite journal |vauthors=Chu AC, Robinson D, Hawk JL, Meacham R, Spittle MF, Smith NP |title=Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis |journal=J. Invest. Dermatol. |volume=86 |issue=2 |pages=134–7 |date=February 1986 |pmid=3528307 |doi= |url=}}</ref>
** Mycosis fangoides
** Mycosis fangoides
***Sezaruy syndrome(SS) is more symptoI contrast to patch or plaque mycosis fungoides (MF), SS is much more symptomatic. Sezary syndrome patients tend to present with diffuse skin involvement,not  like mycosis fungoides usually evolve through patches and plaques to erythroderma <ref name="pmid27407986">{{cite journal |vauthors=Chand K, Sayal SK, Chand S |title=Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |journal=Med J Armed Forces India |volume=63 |issue=2 |pages=188–90 |date=April 2007 |pmid=27407986 |pmc=4925357 |doi=10.1016/S0377-1237(07)80076-1 |url=}}</ref>
***Sezaruy syndrome(SS) is more symptoI contrast to patch or [[plaque]] [[mycosis fungoides]] (MF), SS is much more [[symptomatic]]. Sezary syndrome patients tend to present with [[diffuse]] [[skin]] involvement,not  like mycosis fungoides usually evolve through [[Patched|patches]] and [[Plaque|plaques]] to [[erythroderma]] <ref name="pmid27407986">{{cite journal |vauthors=Chand K, Sayal SK, Chand S |title=Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |journal=Med J Armed Forces India |volume=63 |issue=2 |pages=188–90 |date=April 2007 |pmid=27407986 |pmc=4925357 |doi=10.1016/S0377-1237(07)80076-1 |url=}}</ref>
***In Sezary syndrome infiltration of skin is generally much less dense than plaque in mycosis fungoides  (MF)
***In Sezary syndrome infiltration of [[skin]] is generally much less dense than [[plaque]] in [[mycosis fungoides]] (MF)
** [[Eczema]]
** [[Eczema]]
** [[Psoriasis]]
** [[Psoriasis]]

Revision as of 15:44, 14 February 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Sezary syndrome must be differentiated from Eczema, Psoriasis, Pityriasis rubra pilaris, dermatitis, Hypereosinophilic syndrome, adult T-cell leukemia, atopic dermatitis, contact dermatitis, chronic actinic dermatitis,scabies, Drug eruption, graft versus host disease.

Differentiating Sezary syndrome from other Diseases

References

  1. ↑ Yamashita T, Abbade LP, Marques ME, Marques SA (2012). "Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update". An Bras Dermatol. 87 (6): 817–28, quiz 829–30. PMC 3699909. PMID 23197199.
  2. ↑ Olek-Hrab K, Silny W (March 2014). "Diagnostics in mycosis fungoides and Sezary syndrome". Rep Pract Oncol Radiother. 19 (2): 72–6. doi:10.1016/j.rpor.2013.11.001. PMC 4054990. PMID 24936324.
  3. ↑ Klemke CD, Brade J, Weckesser S, Sachse MM, Booken N, Neumaier M, Goerdt S, Nebe TC (September 2008). "The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers". Br. J. Dermatol. 159 (4): 871–80. doi:10.1111/j.1365-2133.2008.08739.x. PMID 18652582.
  4. ↑ Scala E, Abeni D, Palazzo P, Liso M, Pomponi D, Lombardo G, Picchio MC, Narducci MG, Russo G, Mari A (2012). "Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome". Int. Arch. Allergy Immunol. 157 (2): 159–67. doi:10.1159/000327553. PMID 21985996.
  5. ↑ Chu AC, Robinson D, Hawk JL, Meacham R, Spittle MF, Smith NP (February 1986). "Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis". J. Invest. Dermatol. 86 (2): 134–7. PMID 3528307.
  6. ↑ Chand K, Sayal SK, Chand S (April 2007). "Cutaneous T-Cell Lymphoma (Mycosis Fungoides)". Med J Armed Forces India. 63 (2): 188–90. doi:10.1016/S0377-1237(07)80076-1. PMC 4925357. PMID 27407986.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Sezary_syndrome_differential_diagnosis&oldid=1550013"